MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arcus Biosciences Inc

Chiusa

SettoreSettore sanitario

9.15 -2.97

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.1

Massimo

9.57

Metriche Chiave

By Trading Economics

Entrata

-18M

-112M

Vendite

2M

28M

Margine di Profitto

-400

Dipendenti

627

EBITDA

-34M

-122M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+168.47% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

56M

1B

Apertura precedente

12.12

Chiusura precedente

9.15

Notizie sul Sentiment di mercato

By Acuity

40%

60%

131 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Arcus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 lug 2025, 21:01 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 20:46 UTC

Utili

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lug 2025, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 20:36 UTC

Utili

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lug 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lug 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 20:02 UTC

Discorsi di Mercato

Gold Higher to Close Out Week -- Market Talk

18 lug 2025, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lug 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lug 2025, 18:24 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lug 2025, 18:19 UTC

Utili

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lug 2025, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lug 2025, 18:11 UTC

Utili

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lug 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lug 2025, 16:29 UTC

Discorsi di Mercato

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lug 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 16:04 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lug 2025, 15:47 UTC

Discorsi di Mercato
Utili

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Confronto tra pari

Modifica del prezzo

Arcus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

168.47% in crescita

Previsioni per 12 mesi

Media 25.29 USD  168.47%

Alto 46 USD

Basso 12 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.01 / 8.75Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

131 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.